# Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence

Source: https://onco.cc/trials/nct04410445/  
OnCo record `nct04410445` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Bempegaldesleukin and Nivolumab in Melanoma, run by Nektar Therapeutics, recorded as terminated on the registry.

## Summary

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence is a phase 3 interventional study registered as NCT04410445 by Nektar Therapeutics, with 765 participants recorded, started 2020-07-27 and due to reach its primary completion in 2022-09-22. Interventions recorded: Bempegaldesleukin, Nivolumab. Conditions recorded: Melanoma, Melanoma Stage III, Melanoma Stage IV, Melanoma (Skin).

Linked to the drug Bempegaldesleukin because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04410445
- Phase: 3
- Setting: A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)
- Sponsor: Nektar Therapeutics
- Enrolled: 765

## Sources

- ClinicalTrials.gov NCT04410445: https://clinicaltrials.gov/study/NCT04410445

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Bempegaldesleukin](https://onco.cc/drugs/bempegaldesleukin/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- companies: [Nektar Therapeutics](https://onco.cc/companies/nektar-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct04410445.json